A prescription used to be the finish line. Today it’s one step in a longer sequence: a hospital’s procurement committee has to approve the product, a payer or national health-insurance authority has to cover it, and the facility’s own protocols have to allow it, before that prescription ever reaches a patient. Across MENA’s consolidating healthcare systems, the customer pharma actually needs to win over is no longer the individual prescriber. It’s the institution standing behind them.
Why the Physician Stopped Being the Whole Decision
Healthcare delivery across the region has consolidated. Hospital groups, insurance authorities, and national payer systems now sit between a physician’s clinical judgment and a patient’s access to treatment. Egypt’s own reforms make the shift concrete: bodies like the Universal Health Insurance (UHI), the Unified Procurement Authority, and the Egyptian Drug Authority now shape what gets covered, purchased, and approved at a system level, not a prescription-pad level. A physician can still want to prescribe a therapy. Whether that patient ever receives it increasingly depends on decisions made somewhere else entirely.
What Institutional Buyers Actually Evaluate
An individual physician can be persuaded by a strong clinical conversation. A procurement committee, a formulary board, or a payer’s technical assessment unit evaluates a product against a completely different set of questions, and clinical efficacy only gets a product evaluated at all.
- Total cost of care, not list price. Institutional buyers weigh acquisition cost against the full downstream cost of treatment: hospitalizations avoided, complications prevented, resources freed up elsewhere in the system.
- Operational and protocol fit. A therapy that integrates smoothly into existing clinical pathways and procurement cycles clears the bar faster than one that demands the system change how it already works.
- Outcomes the institution is actually measured on. Hospitals and payers are increasingly evaluated on quality scores and population-level outcomes, so a value story has to speak to their metrics, not just the brand’s.
What This Means for Account Teams
None of this can be handled by a generalist call plan built around one prescriber at a time. It requires knowing who actually sits on the committee, what each of them is accountable for, and how commercial, medical and market access teams coordinate around that same account instead of pursuing it with three different messages. Mapping the real decision-makers inside an institution, and building one coherent account strategy around them, has stopped being a specialist add-on and become the baseline for competing in a consolidated market.
The Takeaway
The physician is still worth winning over. But treating that conversation as the whole sale misreads how access decisions actually get made today. The organizations pulling ahead are the ones who’ve stopped asking “how do we reach more doctors” and started asking “who, inside this institution, actually decides, and what do they need to see before they say yes.”
Back to Insights